Biotech & Life Sciences
Expert Radiation Shielding for Hospitals and Imaging Centers Across the U.S.
Lead Glass Pro, a U.S.-based supplier of radiation shielding products, is continuing to expand its capabilities to support hospitals, imaging centers, and construction teams across the country. The company provides materials and technical expertise for X-ray, CT, fluoroscopy, cath lab, nuclear medicine, and interventional imaging rooms. Medical imaging construction projects require strict compliance with federal,…
Breakthrough in Wound Care: MolecuLightDX Earns FDA MDDT Status
MolecuLight announced that its MolecuLightDX® wound measurement system has been qualified by the U.S. Food and Drug Administration (FDA) as a Medical Device Development Tool (MDDT). This program validates scientifically proven tools for use in medical device development, allowing sponsors to generate reliable, FDA-accepted data during clinical trials. What This Means MolecuLightDX: A Unique Wound…
Intellia Stock Rises on FDA Clearance for CRISPR Therapy
NTLA performance by TradingView Intellia Therapeutics (NASDAQ: NTLA) saw shares rise after the FDA lifted a clinical hold on one of its Phase 3 trials for nexiguran ziclumeran (nex-z), a CRISPR-based therapy for transthyretin amyloidosis (ATTR). What Happened Last October, U.S. regulators paused two trials after a participant died from severe liver toxicity. The cleared…
From Biotech CEO to Prison: Inside the CytoDyn Fraud Case
CYDY performance by TradingView A former biotech executive has been sentenced to prison after being found guilty of misleading investors and selling his own shares at inflated prices. Nader Pourhassan, 62, of Lake Oswego, Oregon, was sentenced to 30 months in federal prison for securities fraud related to false claims about a drug his company…
New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits
BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI IQLIK, for people with early Alzheimer’s disease. The FDA has given it Priority Review, with a decision expected by May 24, 2026. If approved, this version…
Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts
SNY performance by TradingView Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to…
Experienced Biotech Executives Launch New Rare Disease Startup
Another rare disease startup is entering the market, this time backed by a group of executives who have been here before. Mendra, a new biotech led by former BioMarin and Escient Pharmaceuticals executives, has raised $82 million in a Series A round led by OrbiMed, 8VC, and 5AM Ventures. The company says the capital will…
China Becomes New Hunting Ground for Obesity Drugs
Corxel’s latest funding round lands at a time when U.S. and European drug developers are increasingly sourcing new medicines from China. Over the past few years, both large pharmaceutical companies and venture-backed biotech firms have shown a willingness to license compounds discovered in Chinese labs and move them quickly into Western clinical programs. That strategy…
New Study Shows Brain Processes Language Like AI Models
For years, neuroscientists have debated how people actually make sense of spoken language. Is it driven by strict rules, or does meaning slowly come together as we hear more words? A new study suggests it is the latter. And interestingly, the process looks a lot like how modern AI language models handle text. What the…
JNJ Earnings Hit Growth, But Patent Losses Threaten Future Sales
Johnson & Johnson (NYSE: JNJ) shares fell about 1 percent in early Wednesday trading as investors digested the company’s latest earnings report. Management highlighted confidence in the business, with CEO Joaquin Duato calling the company’s lineup the strongest it has ever had. The market response suggested lingering doubts. Concerns remain around patent losses, litigation exposure,…
